Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Latin American and Caribbean countries will aim to reduce new cases of HIV by 75 percent by 2020, according to the Pan American Health Organization. The […]
With the deadline for submitting a national action plan to combat multidrug-resistant tuberculosis quickly approaching, a group of Senators has sent a letter to the White […]
Study finds diversity in costs, support, and implementation of recommended antiretroviral treatment monitoring
It’s the best way to ensure antiretroviral treatment is working for those getting it, protecting their immune systems and preventing illness and transmission — and the […]